Skip to main content
. 2018 Mar 7;13(3):e0192949. doi: 10.1371/journal.pone.0192949

Fig 4. Comparison of MMPs expression after the simulation in IBD simulated individuals of different therapies.

Fig 4

Simulated therapies: Anti-TNFα, GMA therapy (equivalent of knock out our MACR node), anti-IL17, human recombinant IL10 (rhulL-10), anti-IFNγ, anti-IL2 and anti-IL12-IL23. Comparing with untreated simulation, we can see a 30.7%, a 27.1%, a 31.9% and a 4.1% decrease in the MMPs expression simulating anti-TNFα, GMA therapy, anti-IL2 and anti-IL12-IL23 respectively. There is no major change in MMPs expression for the two which failed in clinical trials anti-IL17 (a 6.5% decrease) and human recombinant IL10 (a 3.2% decrease). Otherwise, anti-IFNγ therapy simulation shows an increase in MMPs expression of 16.0% compared to Untreated.